



PRESS RELEASE

Oncodesign announces its financial calendar for 2016

Dijon (France), January 11, 2016 – ONCODESIGN (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious diseases with no known effective treatment, announces its financial calendar for 2016.

- Wednesday, January 20, 2016:** Publication of full year 2015 revenues (after market)
Tuesday, March 29, 2016: Publication of full year 2015 results (after market)
Monday, July 18, 2016: Publication of half year 2016 revenues (after market)
Monday, September 19, 2016: Publication of half year 2016 results (after market)

Beyond these periodicals, investors are invited to consult the website of the company (www.oncodesign.com) where information is regularly updated. All corporate and financial information on the company is available on the company's website, in the Finance' section.

This schedule is indicative and subject to change.

About ONCODESIGN: www.oncodesign.com

Founded 20 years ago by Dr. Philippe Genne, the Company's CEO and Chairman, ONCODESIGN is a biotechnology company that maximizes the pharmaceutical industry's chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment. Backed by unique experience acquired through more than 600 clients, including the world's largest pharmaceutical companies, and relying on a comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modeling and medical imaging, ONCODESIGN is able to predict and identify for every molecule, very upstream, its therapeutic use and its potential to become an efficient drug. Applied to kinase inhibitors, molecules that represent a market estimated at over 40 billion dollars in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D investments, ONCODESIGN's technology has already enabled the targeting of 7 promising molecules with substantial therapeutic potential, in oncology and elsewhere, and the signing of partnerships, potentially worth €350 million in upfront payments should predefined milestones be reached, with pharmaceutical groups Sanofi, Ipsen and UCB. Based in Dijon, France, in the heart of the town's university and hospital hub, ONCODESIGN has 103 staff.

Contacts

Oncodesign
Philippe Genne
CEO
Tel. : +33 3 80 78 82 60
investisseurs@oncodesign.com

NewCap
Investor Relations & Financial Communication
Julien Perez / Nicolas Merigeau
Tel. : +33 1 44 71 98 52
oncodesign@newcap.eu

ALONC
LISTED
ALTERNEXT